Patisiran Sodium News
Patisiran Sodium currently has 0 news articles, with 20 predicted indications.
This page combines the AI-predicted indications for Patisiran Sodium with the latest health news. Indications highlighted in orange have recent news coverage.
Drug Information
- Original indication: Onpattro is indicated for the treatment of hereditary transthyretin-mediated amyloidosis (hATTR amyloidosis) in adult patients with stage 1 or stage 2 polyneuropathy.
- Evidence level: L5
- Predicted indications (20):
- dermatitis (90.7%)
- hydroa vacciniforme, familial (90.1%)
- amyopathic dermatomyositis (90.1%)
- acne keloid (90.0%)
- secondary interstitial lung disease specific to childhood associated with a connective tissue disease (90.0%)
- neonatal dermatomyositis (89.9%)
- acrodermatitis chronica atrophicans (89.1%)
- Smouldering systemic mastocytosis (85.1%)
- overactive bladder (disease) (84.9%)
- lymphoadenopathic mastocytosis with eosinophilia (84.6%)
- systemic mastocytosis (84.6%)
- angioedema (84.0%)
- gastrin secretion abnormality (83.0%)
- low compliance bladder (81.1%)
- hepatic infarction (79.6%)
- HER2 positive breast carcinoma (79.2%)
- peliosis hepatis (79.2%)
- hepatic veno-occlusive disease (79.0%)
- bladder neck obstruction (78.5%)
- mixed-type autoimmune hemolytic anemia (78.4%)
Related News (0)
No related news yet. When news mentions this drug, it will be collected and shown here automatically.
Disclaimer: The news on this page is collected automatically and is for research reference only; it does not constitute medical advice.